Compare · LLY vs PGEN
LLY vs PGEN
Side-by-side comparison of Eli Lilly and Company (LLY) and Precigen Inc. (PGEN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LLY and PGEN operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.18T, about 457.4x PGEN ($2.58B).
- Over the past year, LLY is up 56.5% and PGEN is up 59.4% - PGEN leads by 2.9 points.
- LLY has been more active in the news (25 items in the past 4 weeks vs 3 for PGEN).
- LLY has more recent analyst coverage (25 ratings vs 5 for PGEN).
- Company
- Eli Lilly and Company
- Precigen Inc.
- Price
- $1257.32+0.45%
- $6.38-11.32%
- Market cap
- $1.18T
- $2.58B
- 1M return
- +9.10%
- -18.77%
- 1Y return
- +56.51%
- +59.43%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 25
- 3
- Recent ratings
- 25
- 5
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Precigen Inc.
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; proprietary methane bioconversion platform that turns natural gas into energy and chemical products; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch inducible gene switch that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with ZIOPHARM Oncology, Inc.; Ares Trading S.A.; Oragenics, Inc.; Intrexon T1D Partners, LLC; Intrexon Energy Partners, LLC; Intrexon Energy Partners II, LLC; Fibrocell Science, Inc.; OvaXon, LLC; S & I Ophthalmic, LLC; Harvest start-up entities; and Surterra Holdings, Inc. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.
Latest LLY
- Lilly confirms date and conference call for third-quarter 2026 financial results announcement
- New composite outcomes data show patients treated with Lilly's Omvoh (mirikizumab-mrkz) achieved comprehensive corticosteroid-free disease control in ulcerative colitis and corticosteroid-free deep remission in Crohn's disease at one year
- Nasdaq Sheds 1.65% as Russell 2000 Sinks to RSI 28, Oil Climbs While Gold and Silver Slide
- Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda
- Record Highs Beckon for Big Caps as Small Caps Lag and Deal Flow Builds
- New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) advance understanding of the interconnected immune and metabolic biology in adults with psoriasis and obesity
- SEC Form 3 filed by Eli Lilly and Company
- Lilly to present new data across its dermatology portfolio with 21 presentations at Fall Clinical 2026, in pursuit of advancing care for chronic skin conditions
- Lilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication from U.S. FDA for certain patients with previously untreated CLL/SLL
- Lilly's oral GLP-1, Foundayo (orforglipron), was associated with significant reductions in predicted long-term risk of type 2 diabetes and cardiovascular disease
Latest PGEN
- B. Riley Securities initiated coverage on Precigen with a new price target
- Chief Financial Officer Thomasian Harry Jr. exercised 53,665 shares at a strike of $2.81, increasing direct ownership by 21% to 311,914 units (SEC Form 4)
- Precigen Receives FDA Platform Technology Designation for AdenoVerse Platform
- Director Kindler Jeffrey B sold $1,376,400 worth of shares (185,000 units at $7.44), decreasing direct ownership by 92% to 17,100 units (SEC Form 4)
- SEC Form 144 filed by Precigen Inc.
- Director Agee Nancy H bought $24,662 worth of shares (3,411 units at $7.23), increasing direct ownership by 1% to 309,187 units (SEC Form 4)
- Chief Legal Officer Lehr Donald P. converted options into 5,208 shares and covered exercise/tax liability with 2,488 shares, increasing direct ownership by 0.36% to 758,181 units (SEC Form 4) (tax liability)
- Chief Financial Officer Thomasian Harry Jr. converted options into 7,291 shares and covered exercise/tax liability with 3,577 shares, increasing direct ownership by 1% to 258,249 units (SEC Form 4) (withholding obligation)
- Chief Operating Officer Shah Rutul R exercised 57,500 shares at a strike of $2.03, sold $375,000 worth of shares (50,000 units at $7.50) as part of a pre-agreed trading plan and covered exercise/tax liability with 3,647 shares, increasing direct ownership by 0.83% to 468,865 units (SEC Form 4) (withholding tax)
- Chief Commercial Officer Tennant Phil exercised 84,374 shares at a strike of $1.51, covered exercise/tax liability with 2,585 shares and sold $593,745 worth of shares (79,166 units at $7.50) as part of a pre-agreed trading plan, increasing direct ownership by 2% to 141,992 units (SEC Form 4) to satisfy withholding tax